Breast Cancer Update: Surgical Edition, Issue 1, 2019
Interview with Charles E Geyer Jr, MD
Track 1:
Case: A premenopausal woman in her mid-40s with Grade II, ER/PR-positive, HER2-negative lobular breast cancer, a 21-gene assay Recurrence Score (RS) of 10 and a deleterious CHEK2 mutation undergoes a bilateral mastectomy
Track 2:
Impact of gene-expression assay results on therapeutic decision-making
Track 3:
Results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate RS
Track 4:
Clinical utility of the 21-gene and 70-gene assays
Track 5:
Benefit with the addition of ovarian function suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence
Track 6:
Approach to assessing the adequacy of ovarian function suppression in premenopausal patients receiving aromatase inhibition
Track 7:
Significance of clinical risk category in prognosis and in the prediction of chemotherapy benefit by age and RS in the TAILORx trial
Track 8:
Use of adjuvant bone-modifying agents to reduce the risk of aromatase inhibitor-associated bone loss and fracture
Track 9:
Role of the 21-gene assay RS in guiding neoadjuvant therapy decision-making for ER-positive, HER2-negative localized breast cancer
Track 10:
Mechanism of action, efficacy and tolerability of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer
Track 11:
Investigation of CDK4/6 inhibitors alone or in combination with endocrine therapy in the neoadjuvant and adjuvant settings
Track 12:
Case: A postmenopausal woman in her mid-50s with Grade I, ER-positive, PR-negative, HER2-negative infiltrating ductal carcinoma (IDC) with 1 positive node and a RS of 20 receives an aromatase inhibitor and denosumab
Track 13:
Approach to the selection of adjuvant endocrine therapy; management of aromatase inhibitor-associated arthralgias
Track 14:
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
Track 15:
Prospective data with and ongoing evaluation of the 21-gene and 70-gene assays for patients with node-positive disease
Track 16:
Results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive localized breast cancer and residual disease after neoadjuvant treatment
Track 17:
Rationale for the design and entry criteria of the KATHERINE study
Track 18:
Mechanism of action, activity and tolerability of antibody-drug conjugates
Track 19:
Second opinion: Therapeutic options for a patient in her mid-40s with recurrent, locally advanced, ER/PR-positive, HER2-positive breast cancer
Track 20:
Clinical implications of the KATHERINE trial results
FACULTY
Charles E Geyer Jr, MD
Professor of Medicine
Virginia Commonwealth University School of Medicine
Harrigan, Haw Luck Families Chair in Cancer Research
Associate Director of Clinical Research
Massey Cancer Center
Richmond, Virginia
Tari A King, MD
Associate Chair for Multidisciplinary Oncology
Department of Surgery
Chief Division of Breast Surgery
Brigham and Women’s Hospital
Dana-Farber/Brigham and Women’s Cancer Center
Anne E Dyson Associate Professor of Surgery
Harvard Medical School
Boston, Massachusetts
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida